Nora Nseir
Founder
Nurami Medical
Nurami Medical develops electrospun nanofiber technologies for surgical applications, creating bio surgical implants that provide watertight closure and promote tissue regeneration. Their ArtiFascia® implant addresses complications in dural repair by preventing leaks and supporting healthy tissue formation, backed by clinical evidence and regulatory approval.
- Biotechnology
Updated 7 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Problem
Current soft tissue implants used in surgical procedures can lead to complications such as dangerous leaks and failure to promote healthy tissue formation. Dural repair, in particular, faces challenges in achieving watertight closure and supporting effective regeneration of the dura mater.
Solution
Nurami Medical develops bio-surgical implants using electrospun nanofiber technology to improve soft tissue repair. Their ArtiFascia® implant is designed for dural repair, providing a biomimetic scaffold that fosters tissue regeneration alongside an integrated thin film to minimize leaks. The multi-layer design of ArtiFascia® aims to provide watertight closure and promote dura regeneration, addressing the limitations of existing soft tissue implants. ArtiFascia® is available in the US market with 510k clearance.
Target Audience
The primary target audience includes neurosurgeons and other surgical specialists focused on soft tissue repair, particularly dural repair procedures.
Features
- Electrospun nanofiber scaffold designed to support tissue regeneration
- Integrated thin film layer to prevent leaks and maintain watertight closure
- Biomimetic design mimicking the natural structure of soft tissues
- Suturable and easy to handle for convenient surgical application
- Clinically evaluated in an 85-patient study demonstrating safety and efficacy
- Strong intellectual property protection
- Regulatory approval (510k) for dural repair applications in the US